|
業務類別
|
Biotechnology |
|
業務概覽
|
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs. The company's operations are organized on a single reportable segment, which includes all activities related to the discovery, development, and commercialization of its CAB products. |
| 公司地址
| 11085 Torreyana Road, San Diego, CA, USA, 92121 |
| 電話號碼
| +1 858 558-0708 |
| 傳真號碼
| +1 858 558-0709 |
| 公司網頁
| https://www.bioatla.com |
| 員工數量
| 41 |
| Dr. Jay M. Short,PhD |
Chairman of the Board and Chief Executive Officer |
美元 734.82K |
31/03/2026 |
| Dr. Eric Sievers, M.D. |
Chief Medical Officer |
美元 510.22K |
24/04/2025 |
| Mr. Christian Vasquez |
Chief Financial Officer, Chief Accounting Officer, Controller and Corporate Secretary |
-- |
02/03/2026 |
|
|
| Professor Lawrence J. Steinman, M.D. |
Lead Independent Director |
31/03/2026 |
| Dr. Mary Ann Gray,PhD |
Independent Director |
31/03/2026 |
| Dr. Jay M. Short,PhD |
Chairman of the Board and Chief Executive Officer |
31/03/2026 |
| Ms. Sylvia McBrinn |
Independent Director |
31/03/2026 |
| Mr. Scott A. Smith |
Director |
31/03/2026 |
| Mr. Edward Williams |
Independent Director |
31/03/2026 |
| Dr. Susan Moran, M.D. |
Independent Director |
31/03/2026 |
|
|
|
|
